February 28, 2024

Healthy About Liver

Masters of Health

Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel

Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

PRINCETON, N.J., July 08, 2022 (World NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare corporation, today announced that Chairman and CEO Al Altomari will be taking part in a digital panel dialogue introduced by Maxim Team LLC and hosted by M-Vest. Full specifics on the panel are as follows:

  • Date/Time: Wednesday, July 13, 2022 at 11:00 a.m. ET

  • Panel Title: “A Tipping Point in Women’s Health and fitness – Does the SCOTUS Consequence Alter the Paradigm in Contraception?”

  • Moderator: Jason McCarthy, Ph.D., Senior Controlling Director and Head of Biotechnology Research – Equity Research at Maxim Team

  • Participating Panelists:

    • Al Altomari, CEO, Agile Therapeutics, Inc. (AGRX)

    • Sabrina Martucci Johnson, CEO, Daré Bioscience, Inc. (DARE)

    • Kathy Lee-Sepsick, CEO, Femasys Inc. (FEMY)

The panel will be hosted on Maxim’s M-Vest web-site and readily available to its associates. For far more information and facts, be sure to visit https://m-vest.com/functions/womens-well being-panel-07132022.

The webcast of the event will be offered on the trader relations page of the Company’s web site at https://ir.agiletherapeutics.com/gatherings-and-shows. The archived webcast will be offered from July 15-July 28, 2022.

About Agile Therapeutics, Inc.
Agile Therapeutics is a ahead-thinking women’s health care firm committed to fulfilling the unmet wellness desires of today’s gals.  Twirla and our product or service candidates are created to present females with contraceptive possibilities that offer you independence from having a everyday pill, without the need of committing to a longer-performing process.  Twirla® and our pipeline products are based mostly on our proprietary transdermal patch technological innovation, termed Skinfusion®, which is designed to permit drug supply by the pores and skin. For a lot more information and facts, make sure you check out the organization web page at  www.agiletherapeutics.com. The Company may once in a while disseminate product, nonpublic details on the Company’s site.

Forward-Hunting Assertion
Specific facts contained in this push release contains “forward-searching statements”, in just the this means of Portion 27A of the Securities Act of 1933, as amended, and Segment 21E of the Securities Exchange Act of 1934, as amended, connected to the Company’s monetary status, the growth of Twirla and the momentum of these development, the achievements of the Company’s key initiatives and their outcome on the Company’s effects, and the execution of the Company’s commercial prepare. We could, in some cases use conditions this kind of as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other text that express uncertainty of the long run situations or results to identify these forward-seeking statements. Our forward-on the lookout statements are dependent on recent beliefs and anticipations of our management workforce that require risks, opportunity adjustments in circumstances, assumptions, and uncertainties, like statements relating to the growth in prescriptions and demand from customers for Twirla, the execution of our commercial and business prepare, and the contribution of sure components of our enterprise strategy to continued progress in Twirla prescription demand from customers. Any or all of the ahead-on the lookout statements may possibly transform out to be completely wrong or be impacted by inaccurate assumptions we could make or by recognised or not known risks and uncertainties. These forward-wanting statements are subject matter to hazards and uncertainties such as hazards linked to our means sustain regulatory approval of Twirla, our potential to successfully commercialize Twirla, regulatory and legislative developments in the United States and overseas countries, our ability to get hold of and maintain mental house defense for Twirla, our approach, organization ideas and emphasis, and the other challenges set forth in our filings with the U.S. Securities and Exchange Commission, such as our Annual Report on Kind 10-K and our Quarterly Stories on Form 10-Q.  For all these factors, real outcomes and developments could be materially diverse from all those expressed in or implied by our forward-wanting statements. You are cautioned not to place undue reliance on these ahead-looking statements, which are created only as of the day of this push release. We undertake no obligation to publicly update this sort of forward-seeking statements to replicate subsequent events or circumstances.

Speak to: 
Matt Riley
Head of Trader Relations
[email protected]